The Beatrice Hunter Cancer Research Institute logo
  • CRTP Integrated Learning Sessions

    Wednesday, September 26, 2018

    • Time: 10:00 am - 12:00 pm
    • Location: Room 2-L7, Tupper Building Link, Dalhousie and videoconference sites as listed

    The Beatrice Hunter Cancer Research Institute CRTP Integrated Learning Session (ILS) will be held on Wednesday 26 September from 10:00am-12:00pm ADT in room 2L7, 2nd floor, Tupper Building Link, Dalhousie University and by videoconference to the following sites:  

    •   Dalhousie Halifax –2L3, Second Floor, Tupper Link
    •   Georges Dumont Hospital - Salle de vidéoconférence-Hémo 3- local 2502
    •   MUN – Meeting room 3 (HSC 2985) 
    •   Dalhousie Truro –Student Learning Commons – SLC Boardroom
    •   CBU – B260-A
    •   UNB St. John – LRC 266
    •   Acadia – BAC144A

    ILS sessions are mandatory for CRTP Trainees – please contact admin@bhcri.ca if you are unable to attend. Trainees recognize the benefit of having supervisors in attendance at these sessions and we hope that all supervisors of CRTP trainees will attend as many sessions as possible.

     

    Genomics and the Diagnosis of Cancers


    Presented by:

    Christopher R. McMaster, PhD, FCAHS
    Scientific Director / Directeur Scientifique, CIHR Institute of Genetics / IRSC Institut de Génétique; Professor of Pharmacology, Dalhousie University

    Dr. Christopher McMaster, PhD, FCAHS, is the Scientific Director of the Canadian Institutes for Health Research, and Professor of Pharmacology in the Faculty of Medicine at Dalhousie University. Previous to this, he was the Carnegie and Rockefeller Head of Pharmacology at Dalhousie University, held a Canada Research Chair (Tier 2) in Biosignalling, and was the Assistant Dean for Graduate and Post-doctoral Studies in the Faculty of Medicine at Dalhousie University.
    Dr. McMaster's research is broad in interest ranging from basic biochemistry and cell biology, to genomics to determine causal genes for human genetic diseases and their amelioration, to ethical and policy considerations as human genomics is being transitioned toward clinical diagnosis and care. Since 2010, he has been a PI or co-PI on over $30 million in grants, with $20 million directed toward his home institution of Dalhousie University. He has led, and currently leads, large research consortia including acting as PI on a Genome Canada large scale applied research project, co-PI on a large Canada Foundation for Innovation grant, and as PI on a large-scale Atlantic Innovation Fund project.  


    Daniel Gaston, PhD 
    Assistant Professor, Department of Pathology, Dalhousie University; Clinical Laboratory Bioinformatician, Department of Pathology and Laboratory Medicine, Division of Hematopathology, Nova Scotia Health Authority

    Dr. Daniel Gaston is a Clinical Bioinformatician with the Nova Scotia Health Authority and Assistant Professor in the Department of Pathology. After completing a PhD in the Department of Biochemistry in 2012 under the supervision of Dr. Andrew Roger he went on to a Post-Doctoral Fellowship with Dr. Karen Bedard trying to identify the genetic causes underlying unknown Mendelian diseases in Atlantic Canada. A particular focus was a form of Familial Gastric Cancer and the identification of associations with the gene MAP3K6. Dr. Gaston was a CRTP trainee in 2014/2015 before taking his full-time position with the NSHA.
    At the NSHA Dr. Gaston has implemented custom bioinformatics analysis pipelines and implemented Next-Generation Sequencing-based tests within the Molecular Diagnostics lab, which now offers these advanced Precision Medicine tools throughout Atlantic Canada for the diagnosis and prognosis of cancer patients.


    PLEASE NOTE: It is important to mute mics when not in use so that background noise is minimal. For technical support during sessions, please phone: 1-855-265-7142 


Site by: Spectacle Group